A focus on Sjogren’s Dry Eye Disease - pathogenesis, patient management, and new advancements in therapy
DOI:
https://doi.org/10.12775/JEHS.2023.37.01.010Keywords
Sjogren's syndrome, Sjogren's syndrome dry eye disease, Sjogren's syndrome new therapies, non-Sjogren's syndrome dry eye, Sjogren's syndrome clinical trialsAbstract
Introduction: Sjogren’s syndrome (SS) is a systemic chronic inflammatory autoimmune disease of unknown etiology that primarily affects exocrine glands. Most commonly Sjogren’s syndrome presents with dryness of the mouth and eyes, but it can also affect major organs and systems of the body and increase the risk of non-Hodgkin lymphoma. Due to non-specific symptoms that pose diagnostic challenges and a lack of standardized screening tools and classification criteria, the global incidence and prevalence of the disease are hard to evaluate. Studies estimate that Sjogren’s syndrome affects between 400,000 to 3.1 million adults worldwide and most likely is a condition significantly underdiagnosed.
Aim of the study: Review of current knowledge about Sjogren’s dry eye disease, underlying pathologies, diagnostic problems, and current treatment options with a focus on the most recent advancements in therapy.
Methods and materials: A review of chosen literature in the PubMed database, MDPI database, and GoogleScholar in the years 2000-2023 was conducted using the following keywords: “Sjogren’s syndrome”, “Sjogren’s syndrome ophthalmology”, “Sjogren’s dry eye syndrome”, “Sjogren’s syndrome associated dry eye”, “Lymphoma in Sjogren’s syndrome”, “Diagnosing Sjogren’s syndrome dry eye”, “Sjogren’s syndrome epidemiology”.
Results: Sjogren’s syndrome is a far from rare autoimmune disease that affects many organs of the body and can significantly lower quality of life and increase mortality and morbidity. Due to its surreptitious symptom onset, Sjogren’s syndrome is commonly underdiagnosed. New diagnostic and treatment modalities for Sjogren’s syndrome dry eye are on the horizon.
Conclusions: Standardized, internationally recognized criteria and a high level of clinical suspiciousness are needed for a timely and accurate diagnosis of Sjogren’s syndrome. Quick diagnosis is a significant facilitating factor for maintaining a high quality of life in Sjogren’s syndrome dry eye.
References
Fragkioudaki S, Mavragani CP, Moutsopoulos HM. Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use. Medicine (Baltimore). 2016 Jun;95(25):e3766. doi: 10.1097/MD.0000000000003766.000003766.
Patel R, Shahane A. The epidemiology of Sjögren's syndrome. Clin Epidemiol. 2014 Jul 30;6:247-55. doi: 10.2147/CLEP.S47399.
Carsons SE, Patel BC. Sjogren Syndrome. 2023 Apr 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 28613703.
Wu KY, Chen WT, Chu-Bédard YK, Patel G, Tran SD. Management of Sjogren's Dry Eye Disease-Advances in Ocular Drug Delivery Offering a New Hope. Pharmaceutics. 2022 Dec 31;15(1):147. doi: 10.3390/pharmaceutics15010147.
Wu KY, Kulbay M, Tanasescu C, Jiao B, Nguyen BH, Tran SD. An Overview of the Dry Eye Disease in Sjögren’s Syndrome Using Our Current Molecular Understanding. International Journal of Molecular Sciences. 2023; 24(2):1580. doi: 10.3390/ijms24021580
Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, Zhong R. Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015 Nov;74(11):1983-9. doi: 10.1136/annrheumdis-2014-205375.
Liao R, Yang HT, Li H, Liu LX, Li K, Li JJ, Liang J, Hong XP, Chen YL, Liu DZ. Recent Advances of Salivary Gland Biopsy in Sjögren's Syndrome. Front Med (Lausanne). 2022 Jan 10;8:792593. doi: 10.3389/fmed.2021.792593.
Tzioufas AG, Goules AV. Limited efficacy of targeted treatments in Sjögren's syndrome: why? Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):27-28. Epub 2018 Jun 21. PMID: 29998826.
Gomes Pde S, Juodzbalys G, Fernandes MH, Guobis Z. Diagnostic Approaches to Sjögren's syndrome: a Literature Review and Own Clinical Experience. J Oral Maxillofac Res. 2012 Apr 1;3(1):e3. doi: 10.5037/jomr.2012.3103.
Baer AN, Akpek EK, Alevizos I; 18-21 April 2018, Washington, DC, USA. 14th International Symposium on Sjögren's Syndrome. Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):241-255. Epub 2018 Aug 27. PMID: 30156551.
Kroese FGM, Haacke EA, Bombardieri M. The role of salivary gland histopathology in primary Sjögren's syndrome: promises and pitfalls. Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):222-233. Epub 2018 Aug 14. PMID: 30156550.
Gomes Pde S, Juodzbalys G, Fernandes MH, Guobis Z. Diagnostic Approaches to Sjögren's syndrome: a Literature Review and Own Clinical Experience. J Oral Maxillofac Res. 2012 Apr 1;3(1):e3. doi: 10.5037/jomr.2012.3103.
Tan X, Chen Y, Foulsham W, Amouzegar A, Inomata T, Liu Y, Chauhan SK, Dana R. The immunoregulatory role of corneal epithelium-derived thrombospondin-1 in dry eye disease. Ocul Surf. 2018 Oct;16(4):470-477. doi: 10.1016/j.jtos.2018.07.005.
Versura P, Giannaccare G, Vukatana G, Mulè R, Malavolta N, Campos EC. Predictive role of tear protein expression in the early diagnosis of Sjögren’s syndrome. Annals of Clinical Biochemistry. 2018;55(5):561-570. doi:10.1177/0004563217750679
Mandal A, Gote V, Pal D, Ogundele A, Mitra AK. Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease. Pharm Res. 2019 Jan 7;36(2):36. doi: 10.1007/s11095-018-2556-5.
Bowman SJ, Fox R, Dörner T, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki JN, Sopala MA, Luo WL, Hueber W. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet. 2022 Jan 8;399(10320):161-171. doi: 10.1016/S0140-6736(21)02251-0.
Milner MS, Beckman KA, Luchs JI, Allen QB, Awdeh RM, Berdahl J, Boland TS, Buznego C, Gira JP, Goldberg DF, Goldman D, Goyal RK, Jackson MA, Katz J, Kim T, Majmudar PA, Malhotra RP, McDonald MB, Rajpal RK, Raviv T, Rowen S, Shamie N, Solomon JD, Stonecipher K, Tauber S, Trattler W, Walter KA, Waring GO 4th, Weinstock RJ, Wiley WF, Yeu E. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment. Curr Opin Ophthalmol. 2017 Jan;27 Suppl 1(Suppl 1):3-47. doi: 10.1097/01.icu.0000512373.81749.b7.
Agmon-Levin N, Kivity S,Tzioufas AG, Hoyos M, Rozman B, Efes I, Shapira Y, Shamis A, Amital H, Youinou P, Shoenfeld Y. Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjögren’s syndrome. Journal of Autoimmunity, Volume 39, Issue 3,2012, Pages 234-239, ISSN 0896-8411, doi: 10.1016/j.jaut.2012.05.018.
Stefanski AL, Tomiak C, Pleyer U, Dietrich T, Burmester GR, Dörner T. The Diagnosis and Treatment of Sjögren's Syndrome. Dtsch Arztebl Int. 2017 May 26;114(20):354-361. doi: 10.3238/arztebl.2017.0354.
Vivino FB. Sjogren's syndrome: Clinical aspects. Clin Immunol. 2017 Sep;182:48-54. doi: 10.1016/j.clim.2017.04.005.
Locatelli EVT, Acuna KA, Betz J, Tovar AA, Galor A. Comparison of Subjective Responses to Cyclosporine 0.05% Versus Lifitegrast 5.0% in Individuals With Dry Eye Disease. Cornea. 2023 Feb 27. doi: 10.1097/ICO.0000000000003266.
Vijmasi T, Chen FY, Balasubbu S, Gallup M, McKown RL, Laurie GW, McNamara NA. Topical administration of lacritin is a novel therapy for aqueous-deficient dry eye disease. Invest Ophthalmol Vis Sci. 2014 Jul 17;55(8):5401-9. doi: 10.1167/iovs.14-13924.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Ewa Uram, Rafał Bogacz, Magdalena Gaik, Inga Magda, Justyna Woźniak , Karol Womperski, Magdalena Osuch
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 268
Number of citations: 0